ClinicalTrials.gg
Status unknownNCT04503902HCCUpdated Nov 29, 2022

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

A Phase 1/2 interventional study of Donafenib Tosilate Tablets and Toripalimab Injection in Advanced Hepatocellular Carcinoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing toripalimab in Carcinoma, Hepatocellular — 2 open to participants now, 5 under way, 3 of them phase 3. toripalimab · Carcinoma, Hepatocellular.

Planned enrollment
11th of 21
46 · median 46
Started
2020
with 5 others
Phase 1/2
3 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
2 of 21
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 21 studies testing toripalimab in Carcinoma, Hepatocellular, this one is the 11th largest by planned enrollment, is one of 6 that started in 2020, is one of 3 in phase 1/2, and was the 12th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 21 studies testing toripalimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing toripalimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study is an open, multi-center phase I/II clinical study.

Read the detailed description

It will explore the tolerability (phase I) and effectiveness (phase II) of the Donafenib tosilate tablets combined with Toripalimab injection in patients with advanced HCC. The study is conducted in two phases, the first phase is the dose exploration phase (phase I), and the second phase is the dose expansion phase (phase II).

03

Conditions studied

  • Advanced Hepatocellular Carcinoma

Keywords

  • HCC
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with locally advanced or HCC who are not suitable for surgical resection, who are clinically diagnosed or confirmed by histopathology and/or cytology according to the "Standards for the Diagnosis and Treatment of Primary Liver Cancer" (2017);
  • At least one (according to v1.1);
  • performance status score of 0 or 1;
  • ≥ 12 weeks;
  • Have not received systemic therapy (systemic chemotherapy and/or molecular targeted therapy).If the patient has received chemotherapy after local treatment, the chemotherapy needs to be over for more than 12 months, and disease progression or metastasis occurs;
  • Fully understand this research and voluntarily sign the ICF。

Exclusion criteria

Exclusion Criteria:

  • Patients with diffuse liver cancer, hepatic encephalopathy that is difficult to control, and liver cancer patients whose lesion size accounts for 70% or more of the entire liver.
  • Patients with intrahepatic cholangiocarcinoma (ICC) or HCC-ICC mixed type;
  • Tumor invades inferior vena cava VP4.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    JS001+Donafenib

    Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv

    Drug: Donafenib Tosilate Tablets · Drug: Toripalimab Injection

Interventions

  • In the dose exploration phase (phase I),three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.

    Also known as: Donafenib

  • JS001 will be administrated by intravenous (i.v.) infusion once every 21 days

    Also known as: JS001

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Severe toxicity that may be related to JS001 or donafenib during dose escalation of phase I clinical trial

    Time frame: 28 days after the first dose of JS001 and Donafenib

  2. Objective response rate(ORR) as determined by the Invertigator using RECIST V1.1

    The ratio of patients who are evaluated as CR or PR

    Time frame: From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months

Secondary outcomes

  1. Anti-JS001 antibody

    Time frame: From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months

  2. Overall survival (OS)

    The Kaplan-Meier survival from the initiation date of first cycle until death from any cause or the last follow-up date.

    Time frame: From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months

  3. Progression free survival (PFS)

    The Kaplan-Meier survival from the initiation date of first cycle until the date of first documented progression or date of death

    Time frame: From the time of initial administration until intolerant toxicity, disease progression, withdrawal of ICF, loss of follow-up, death or early study termination occurs (whichever occurs first),assessed up to 18 months

07

Study locations

1 of 1 sites recruiting
  • No.81 Hospital of PLA
    Nanjing, Jiangsu 215006, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Dec 2023, 38 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 38 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2020
First posted
Aug 7, 2020
StartActual
Oct 15, 2020
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04503902
Responsible party
Sponsor
First posted
Aug 7, 2020
Start date
Oct 15, 2020
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Nov 29, 2022

Study contacts

Shukui Qin, PhD
Contact
qinsk@csco.org.cn
+86-025-80864541
Shukui Qin, PhD
principal investigator · No.81 Hospital of PLA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Donafenib tosylate · Toripalimab

Start the discussion